Last reviewed · How we verify

Molecule 129 — Competitive Intelligence Brief

Molecule 129 (TAGRAXOFUSP) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD123 Interaction [EPC]. Area: Oncology.

marketed CD123 Interaction [EPC] Elongation factor 2 Oncology Recombinant protein Live · refreshed every 30 min

Target snapshot

Molecule 129 (TAGRAXOFUSP) — Stemline Therapeeutics Inc. Tagraxofusp works by binding to CD123 on cancer cells, causing them to die.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Molecule 129 TARGET TAGRAXOFUSP Stemline Therapeeutics Inc marketed CD123 Interaction [EPC] Elongation factor 2 2018-01-01
Azacitidine combined HHT Azacitidine combined HHT Shandong Provincial Hospital phase 3 Hypomethylating agent combined with protein synthesis inhibitor DNA methyltransferase (DNMT) and eukaryotic translation elongation factor 2 (eEF-2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD123 Interaction [EPC] class)

  1. Stemline Therapeeutics Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Molecule 129 — Competitive Intelligence Brief. https://druglandscape.com/ci/tagraxofusp. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: